Enveric Biosciences to out-license psilocin prodrug to MindBio [Pharmaceutical Technology]
Wednesday, May 15, 2024 1 min read
Key Takeaway: Enveric Biosciences has signed a non-binding term sheet with MindBio Therapeutics to out-license a class of psilocin prodrugs. These prodrugs are designed to treat mental health disorders by metabolizing and releasing therapeutic levels of psilocin at varying rates. This collaboration could enhance treatment options in mental health.
Price reaction · baseline $147.69 (2024-05-14 close) · hit pre-market · 5 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-4%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is collaborating with MindBio Therapeutics.
The psilocin prodrugs target mental health disorders.
The prodrugs are designed for controlled release of psilocin.
Full Press Release Details
Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics for the out-licensing of a class of psilocin prodrugs (NPP) aimed at treating mental health disorders. The NPP molecules are created to metabolise and release therapeutic systemic psilocin levels at varying rates.
Full Article >>
Frequently Asked Questions
What is the purpose of the psilocin prodrugs?
The psilocin prodrugs aim to treat mental health disorders.
Who is collaborating with Enveric Biosciences?
MindBio Therapeutics is collaborating with Enveric Biosciences.
How do the psilocin prodrugs work?
They metabolize and release therapeutic levels of psilocin at varying rates.